Rankings
▼
Calendar
NTLA FY 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
NTLA
Intellia Therapeutics, Inc.
$2B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$68M
+16.9% YoY
Gross Profit
$52M
76.5% margin
Operating Income
-$441M
-651.7% margin
Net Income
-$413M
-609.9% margin
EPS (Diluted)
$-3.81
Cash Flow
Operating Cash Flow
-$349M
Free Cash Flow
-$355M
Stock-Based Comp.
$154M
Balance Sheet
Total Assets
$842M
Total Liabilities
$171M
Stockholders' Equity
$671M
Cash & Equivalents
$155M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$68M
$58M
+16.9%
Gross Profit
$52M
$48M
+8.7%
Operating Income
-$441M
-$534M
+17.5%
Net Income
-$413M
-$519M
+20.5%
← Q4 2024
All Quarters
Q1 2025 →